| scholarly article | Q13442814 |
| P356 | DOI | 10.1159/000148914 |
| P953 | full work available at URL | https://www.karger.com/Article/Pdf/148914 |
| https://europepmc.org/articles/PMC2974980 | ||
| https://doi.org/10.1159/000148914 | ||
| https://europepmc.org/articles/PMC2974980?pdf=render | ||
| http://www.karger.com/Article/Pdf/148914 | ||
| P932 | PMC publication ID | 2974980 |
| P698 | PubMed publication ID | 21076605 |
| P5875 | ResearchGate publication ID | 47792002 |
| P2093 | author name string | Marc L. Citron | |
| P2860 | cites work | Dose-dense adjuvant chemotherapy in early breast cancer patients: results from a randomized trial | Q33369478 |
| Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer | Q34601123 | ||
| A phase II pilot trial incorporating bevacizumab into dose-dense doxorubicin and cyclophosphamide followed by paclitaxel in patients with lymph node positive breast cancer: a trial coordinated by the Eastern Cooperative Oncology Group | Q35693076 | ||
| The Norton-Simon hypothesis: designing more effective and less toxic chemotherapeutic regimens | Q36559273 | ||
| HER2 expression and efficacy of dose-dense anthracycline-containing adjuvant chemotherapy in breast cancer patients | Q36614830 | ||
| The importance of dose intensity in the outcome of chemotherapy | Q39514242 | ||
| Analysis of the prognostic effects of inclusion in a clinical trial and of myelosuppression on survival after adjuvant chemotherapy for breast carcinoma | Q40701794 | ||
| Evolving concepts in the systemic drug therapy of breast cancer | Q41579743 | ||
| Dose-Dense Therapy | Q41966433 | ||
| Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. | Q44362100 | ||
| A single scale for comparing dose-intensity of all chemotherapy regimens in breast cancer: summation dose-intensity | Q44924307 | ||
| The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer. | Q46716138 | ||
| Dose density in breast cancer: a simple message? | Q46839622 | ||
| Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342. | Q49273085 | ||
| Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leu | Q57578575 | ||
| Impact of dose-intense chemotherapy on the development of permanent drug resistance | Q69457915 | ||
| Dose: a critical factor in cancer chemotherapy | Q72154949 | ||
| Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results | Q72473268 | ||
| Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up | Q72596355 | ||
| Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-25 | Q73153238 | ||
| Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B | Q77156165 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | chemotherapy | Q974135 |
| P304 | page(s) | 251-255 | |
| P577 | publication date | 2008-08-20 | |
| P1433 | published in | Breast Care | Q15764648 |
| P1476 | title | Dose-Dense Chemotherapy: Principles, Clinical Results and Future Perspectives | |
| P478 | volume | 3 |
| Q36058245 | A way forward on the medically appropriate use of white cell growth factors |
| Q91872279 | Adjuvant Dose-Dense Chemotherapy for Breast Cancer: Available Evidence and Recent Updates |
| Q61443529 | Cardiac involvement in disseminated diffuse large B-cell lymphoma, successful management with chemotherapy dose reduction guided by cardiac imaging: A case report and review of literature |
| Q64238598 | Case report of long-term survival with metastatic triple-negative breast carcinoma: Treatment possibilities for metastatic disease |
| Q53627660 | Comparison of doxorubicin-cyclophosphamide with doxorubicin-dacarbazine for the adjuvant treatment of canine hemangiosarcoma. |
| Q27001627 | Comparison of pegfilgrastim prescribing practice to national guidelines at a university hospital outpatient oncology clinic |
| Q97542023 | Current State of the Art in the Adjuvant Systemic Treatment of Premenopausal Patients With Early Breast Cancer |
| Q38666130 | Dose dense carboplatin paclitaxel improves progression free survival in patients with endometrial cancer |
| Q33408942 | Dose-dense cisplatin-based chemotherapy and surgery for children with high-risk hepatoblastoma (SIOPEL-4): a prospective, single-arm, feasibility study |
| Q43886949 | Dose-intensive cisplatin for hepatoblastoma: have you heard? |
| Q33411751 | Efficacy and tolerability of chemotherapy with modified dose-dense TCF regimen (TCF-dd) in locally advanced or metastatic gastric cancer: final results of a phase II trial |
| Q48376586 | Jekyll and Hyde of chemotherapy treatment: Method for patient-specific dosing of chemotherapy medications. |
| Q55070923 | Lapatinib-associated mucocutaneous toxicities are clinical predictors of improved progression-free survival in patients with human epidermal growth factor receptor (HER2)-positive advanced breast cancer. |
| Q33865098 | Metastatic triple-negative breast cancer patient with TP53 tumor mutation experienced 11 months progression-free survival on bortezomib monotherapy without adverse events after ending standard treatments with grade 3 adverse events |
| Q33749066 | Model-based meta-analysis for quantifying Paclitaxel dose response in cancer patients |
| Q37505622 | Modelling semi-attributable toxicity in dual-agent phase I trials with non-concurrent drug administration |
| Q35909577 | Multimarker Analysis of Circulating Tumor Cells in Peripheral Blood of Metastatic Breast Cancer Patients: A Step Forward in Personalized Medicine |
| Q26751249 | Neoadjuvant Dose-Dense and Dose-Intensified Chemotherapy in Breast Cancer - Review of the Literature |
| Q92669417 | Specific, reversible G1 arrest by UCN-01 in vivo provides cytostatic protection of normal cells against cytotoxic chemotherapy in breast cancer |
| Q35946514 | The dynamics of drug resistance: a mathematical perspective |
Search more.